This site has been produced by Kite, a Gilead Company

Tests and Checks

Before you start CAR T treatment your healthcare team will perform a number of checks which may include:

Bullet
Your general health, or ‘performance status’
Bullet
Check your lungs, heart and blood pressure
Bullet
Look for signs of infection; any infection will be treated
Bullet
Check if your cancer is getting worse
Bullet
Look for signs of graft-versus-host disease that can happen after a transplant (if you have had one)
Bullet
Check your blood for uric acid and for how many cancer cells there are in your blood.
Bullet
Check for hepatitis B, hepatitis C or HIV infection
Bullet
Check if you had a vaccination in the previous 6 weeks or are planning to have one in the next few months

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.

United Kingdom: Reporting of side effects

For patients residing in the United Kingdom, you can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of your medicine.

Republic of Ireland: Reporting of side effects

For patients residing in the Republic of Ireland, you can also report side effects directly via the HPRA website at www.hpra.ie. By reporting side effects, you can help provide more information on the safety of your medicine.

This site is a patient information resource, intended only for patients residing in the United Kingdom and Ireland who are being referred for or have been prescribed CAR T-cell therapy by their healthcare professional. This site has been developed and paid for by Kite, a Gilead Company.

This site has been produced by Kite, a Gilead Company

© 2024 Gilead Sciences, Inc. All rights reserved. KITE and the Kite logo are registered trademarks of Kite Pharma, Inc | GILEAD is a registered trademark of Gilead Sciences, Inc and its related companies

UK-UNB-3793 April 2023